Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Harinder Singh (NPI 1043300510)

Field	Value
Entity Type	Individual
Organization	Harinder Singh
Address	202 10th St Se
City	Cedar Rapids
State	IA
ZIP	52403
Taxonomy	Rheumatology Physician
NPI Enumerated	October 13, 2006

Payer Source	Total Paid
Medicare	$789.3K
Medicaid	$0

Key Findings

This provider reports total Medicare revenue of $789.3K and has no Medicaid billing on file (none below), making the practice effectively single-payer with Medicare as the dominant revenue source. The absence of Medicaid activity suggests limited state-program exposure and places contracting and reimbursement risk squarely on Medicare payment trends and beneficiary volumes.

Revenue is highly concentrated in biologic injectable and infusion drugs: the top three Medicare codes (J1602, J3262, J0129) together account for 69.4% of the provider's Medicare revenue. Individually, J1602 contributes $226.4K (28.0% of Medicare revenue), J3262 contributes $177.2K (22.0%), and J0129 contributes $156.4K (19.4%), indicating the practice’s financial reliance on a small set of high-cost specialty medications.

The procedure mix and code-level detail point to an infusion-focused rheumatology practice: high-revenue drugs J1602 (golimumab IV), J3262 (tocilizumab), J0129 (abatacept) and J1745 (infliximab) are the primary drivers, while administration and infusion CPTs such as 96413 (233 claims, $22.4K revenue) and 96365 (108 claims, $5K revenue) appear in the top codes, consistent with on-site infusion services rather than purely office-based visits.

Despite the biologic-heavy revenue profile, evaluation-and-management visits are a small share of revenue: 99214 accounts for $35.8K (4.4% of Medicare revenue) and 99213 accounts for $8.1K (1.0%), suggesting clinical encounters may be driven by medication administration workflows rather than high-volume office visit billing. This pattern is consistent with a practice model that centers on infusion therapy for chronic rheumatologic conditions.

The provider’s competitive standing versus national Medicare peers is mixed: J1602 ranks #287 of 1041 providers nationally (73th percentile) and is described as typical, unremarkable volume for this code, indicating a solid but not dominant position for that drug. By contrast, J0129 ranks #936 of 1221 (23th percentile; typical, unremarkable volume), and J3262 ranks #346 of 618 (44th percentile; typical, unremarkable volume), together painting a picture of modest national participation across these biologic therapies rather than market leadership.

Multiple laboratory and phlebotomy CPTs appear at relatively high percentiles—86140 (760 claims, $3.8K revenue; 93th percentile; typical, unremarkable volume), 85652 (783 claims, $2.3K revenue; 94th percentile; typical, unremarkable volume), 36415 (548 claims, $4.4K revenue; 90th percentile; typical, unremarkable volume), and panels such as 80053 and 85025 (each near the 89th percentile). These high relative ranks, even while labeled typical in the source, imply above-average in-office lab utilization or frequent test ordering compared with peers and suggest internal workflows that support diagnostic monitoring tied to immunomodulatory therapy.

The presence of chemotherapy/infusion-related administration codes (96413, 96415, 96365, 96375) alongside high-revenue biologic J-codes supports an operational capacity for prolonged infusions and monitored drug administration rather than one-off injections. This operational footprint has implications for staffing, infusion-chair capacity, and revenue-cycle processes centered on drug acquisition and reimbursement.

The provider has an established NPI tenure (NPI enumerated on 2006-10-13 (~20 years ago)), indicating long-term presence in the market. Coupled with $789.3K in lifetime Medicare revenue and the concentrated reliance on a few biologic J-codes, this suggests a stable, specialty-focused practice where managing biologic drug reimbursement and supply is likely the core administrative and financial priority.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

40 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	20,580	$10	$226.4K
J3262	Injection, tocilizumab, 1 mg	35,440	$10	$177.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	4,600	$30	$156.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,910	$30	$101.7K
J0897	Injection, denosumab, 1 mg	2,040	$20	$36.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	410	$90	$35.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	230	$100	$22.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	140	$60	$8.1K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	60	$110	$6.6K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	600	$10	$6K

Showing 1–10 of 40

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 40 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Harinder Singh — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

40 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	5	10	35,440	$1	$233.1K
J0129	12	20	5,950	$30	$218.3K
J1602	3	10	13,010	$10	$153.6K
J1745	10	20	3,460	$30	$92.3K
J0897	90	190	1,920	$20	$74.1K
96413	34	80	210	$90	$24K
99214	674	4,690	100	$70	$14.4K
99213	1,677	4,740	100	$50	$8K
96365	28	80	70	$40	$5.1K
99204	477	1,870	30	$100	$5K

Showing 1–10 of 40

Related Providers

Other providers that share a Tax Identification Number (TIN) with Harinder Singh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Physicians' Clinic Of Iowa, PC	IA	Surgery Physician	$0	$4.9M
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
James Singer	IA	Retina Specialist (Ophthalmology) Physician	$4.1M	$0

Nearby Providers

Other providers in the same ZIP code as Harinder Singh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Medical Center	IA	General Acute Care Hospital	$0	$26.4M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$24.5M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$18.5M
Eastern Iowa Health Center	IA	General Practice Dentistry	$0	$14.4M
Linn County Emergency Medicine PC	IA	Emergency Medicine Physician	$0	$9.8M
C R Iv Service Inc	IA	Home Infusion Therapy Pharmacy	$0	$5.8M
Mercy Medical Center	IA	Cardiovascular Disease Physician	$0	$5.1M
C R Pharmacy Service Inc	IA	Oxygen Equipment & Supplies (DME)	$0	$2.4M
Bogdan Cherascu	IA	Rheumatology Physician	$2.4M	$0
Vijay Aluri	IA	Rheumatology Physician	$2M	$0

Harinder Singh — Billing Profile & Reimbursement Data

Sign up for Harinder Singh — Billing Profile & Reimbursement Data policy alerts

Harinder Singh — Billing Profile & Reimbursement Data

Sign up for Harinder Singh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References